You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review
Roche Holding AG (RHHBY - Free Report) announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for its blockbuster PD-L1 inhibitor, Tecentriq as a chemotherapy free option to treat newly diagnosed patients with certain types of advanced non-small cell lung cancer (NSCLC).
The sBLA is looking to get Tecentriq approved, as a monotherapy, for first-line treatment of PD-L1-selected patients with advanced non-squamous or squamous NSCLC without ALK or EGFR mutations.
With the FDA granting priority review to the sBLA, a decision is expected on Jun 19. The sBLA is based on data from the phase III IMpower110 study. Data from the study showed that Tecentriq alone demonstrated a significant improvement in overall survival compared with chemotherapy in the above patient population.
Roche’s stock has rallied 29.2% in the past year, outperforming the industry’s rise of 9.3%.
Tecentriq is presently approved for several cancer indications either as a monotherapy or in combination with other drugs. Its approved indications include NSCLC, small cell lung cancer, certain types of metastatic urothelial cancer, and in PD-L1-positive metastatic triple-negative breast cancer.
Roche is working to expand the drug’s label further. The company currently has several phase III studies evaluating Tecentriq in lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers, either alone or in combination with other drugs.
Tecentriq sales came in at CHF 1.9 billion in 2019, up 143%. If approved for further indications and in earlier-line settings for approved indications, sales can be higher in the future quarters.
However, competition is stiff in the first-line NSCLC market. Merck’s (MRK - Free Report) PD-L1 inhibitor, Keytruda commands a strong place in first-line NSCLC market. Bristol-Myers Squibb Company’s (BMY - Free Report) PD-L1 inhibitor, Opdivo is also in the race for first-line NSCLC treatment. Its regulatory application seeking approval of Opdivo plus Yervoy for the treatment of first-line NSCLC is under priority review. Other PD-L1 inhibitors available in the market are AstraZeneca’s (AZN - Free Report) Imfinzi and Pfizer’s Bavencio.
Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>